Finance

Beta
Ask
Lists
CMPX:NASDAQ
Compass Therapeutics Inc.
$2.10
0.00%
(0.00) 1D
Jun 22, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CMPX...
Mkt. cap
378.18M
Avg. vol.
4.54M
Volume
42.17K
52-wk high
$6.88
52-wk low
$1.61
EPS
-$0.41
Beta
0.75
Shares outstanding
180.09M
No. of employees
39
Mkt. cap
378.18M
Avg. vol.
4.54M
Volume
42.17K
52-wk high
$6.88
52-wk low
$1.61
EPS
-$0.41
Beta
0.75
Shares outstanding
180.09M
No. of employees
39
News stories
From sources across the web
About Compass Therapeutics Inc.
CEO-
Employees39
Founded2014
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitecompasstherapeutics.com
Analyst Ratings
Based on 11 analysts giving stock ratings to CMPX in the past 3 months
Strong Buy
Buy
10
Hold
1
Sell
0
12 month forecast
Based on 11 Wall Street analysts offering 12 month price targets for CMPX in the last 3 months.
Highest
Current $2.10
$24.00 (+1,042.86%)
Average
$9.38 (+346.67%)
Lowest
$4.00 (+90.48%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Biren Amin
Piper Sandler
Buy
Maintained
$4.00
+90.5%
06/01/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$6.00
+185.7%
06/01/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$24.00
+1,042.9%
06/01/2026
John Newman
Canaccord Genuity
Buy
Maintained
$7.00
+233.3%
05/22/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$6.00
+185.7%
05/09/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
-
-
05/06/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$8.00
+281%
05/06/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
05/05/2026
Sean McCutcheon
Raymond James
Hold
Downgraded
-
-
04/28/2026
Maury Raycroft
Jefferies
Buy
Maintained
$9.00
+328.6%
04/27/2026
Andrew Berens
Leerink Partners
Buy
Maintained
$11.00
+423.8%
04/27/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$8.00
+281%
03/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
16.42M
12.83M
13.67M
13.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.65M
2.99M
4.32M
6.91M
Operating expense
21.07M
15.82M
17.99M
20.30M
Total operating expenses
21.07M
15.82M
17.99M
20.30M
Operating income
-21.07M
-15.82M
-17.99M
-20.30M
Other non operating income
-15.00K
-
-
-
EBT including unusual items
-19.88M
-14.26M
-15.72M
-18.32M
EBT excluding unusual items
-19.88M
-14.26M
-15.72M
-18.32M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-19.88M
-14.26M
-15.72M
-18.32M
Net profit margin
-
-
-
-
Earnings per share
-0.14
-0.08
-0.09
-0.10
Interest and investment income
1.20M
1.56M
2.27M
1.98M
Interest expense
-
-
-
-
Net interest expenses
1.20M
1.56M
2.27M
1.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.97M
-15.80M
-17.97M
-20.28M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer